Learning From COVID-19: The Lessons For Real World Data
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Your Edge In Biotech.
About David Shaywitz
David Shaywitz, MD PhD is a contributing writer for Timmerman Report.
Focus: the transformational opportunities and implementation challenges presented by emerging technologies in healthcare, biomedical discovery, and biopharmaceutical development, from NGS and cell therapies to digital biomarkers and the meaningful application of AI. Co-author (with Lisa Suennen): Tech Tonics: Can Passionate Entrepreneurs Heal Healthcare With Technology? (Hyperink Press, 2014).
Background: physician-scientist+management consultant, experience in drug development, strategic and commercial planning, tech+health.
Job: I am the founder of Astounding HealthTech, an advisory firm focused on the intersection of biopharma and health technology. Previously, I was Senior Partner, Takeda Ventures, Inc. (corporate/strategic VC focused on early-stage life science), and retain equity interest in DNAnexus from previous Chief Medical Officer role.
Other: I maintain a relationship with the Department of Biomedical Informatics, Harvard Medical School; I am also an Adjunct Scholar, American Enterprise Institute. Twitter: @DShaywitz (broadcast only; I do not engage on the platform). Views=my own, and may not represent the views of any organization with which I’m affiliated. For additional info, please see my personal website here.
Latest Contributions
Tech Impact Requires Deep Engagement With Biopharma Lead Users
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
An Underappreciated Aspect of Power: Listening
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Closing Medicine’s Feedback Gap: Can Tech Help Integrate Clinical Care and Clinical Research?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Jill Hagenkord’s Rags To Riches Story Reminds Us Why We Still Admire Entrepreneurs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Clinical Trials: High-Value Attack Surface For Pharmatech Entrepreneurs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Can Novartis Digitally Transform Clinical Development?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
AstraZeneca Opens Its Digital Komono
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More